Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0360-3016(83)90201-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Quality-of-Life Data in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors Using Four Assessment Tools.
Cancers (Basel)
February 2025
Department of Oncology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Purpose: To evaluate the impact of the type of CDK4/6 inhibitor administered and comorbidities on the quality of life in patients with metastatic breast cancer, as well as the correlation between quality of life and patient outcomes.
Materials And Methods: This prospective single-center study utilized four internationally validated questionnaires: the EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Core Cancer Quality of Life Questionnaire), the Depression, Anxiety, and Stress Scale-21 (DASS-21), the Multidimensional Fatigue Inventory (MFI), and the Pittsburgh Sleep Quality Index (PSQI), administered to a cohort of 76 patients undergoing treatment for metastatic breast cancer with CDK4/6 inhibitors.
Results: Ribociclib is associated with fewer insomnia problems and appears to provide better sleep quality compared to other CDK4/6 inhibitors.
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.
Adv Ther
March 2025
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou, 510060, People's Republic of China.
Introduction: Tislelizumab plus investigator-chosen chemotherapy (ICC) demonstrated a statistically significant improvement in overall survival (OS) versus placebo plus ICC in RATIONALE-305 in patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric cancer/gastroesophageal junction cancer (GC/GEJC) in the intent-to-treat population and in patients with programmed death-ligand 1 (PD-L1) Tumor Area Positivity (TAP) score ≥ 5%. The United States Food and Drug Administration Oncologic Drugs Advisory Committee voted (September 2024) against first-line treatment with programmed cell death protein-1 inhibitors in this setting in patients with a PD-L1 combined positive score < 1 or TAP score < 1%, due to an unfavorable benefit-risk profile. Thus, we retrospectively analyzed data from RATIONALE-305 in patients with a PD-L1 TAP score ≥ 1%.
View Article and Find Full Text PDFScreening for cognitive impairment in routine clinical oncology practice: a pilot study using patient-reported outcome measures and online cognitive testing in melanoma and breast cancer patients.
Support Care Cancer
March 2025
Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Purpose: This pilot study aimed to identify patients with cognitive impairment by a stepped-care use of patient-reported outcome measures (PROMs) and complementary online cognitive tests implemented in routine clinical practice.
Methods: Self-reported cognitive functioning was measured in breast cancer or melanoma patients, 6 months after start of treatment, with two items of the EORTC QLQ-C30. Scores below a predefined threshold of 75 indicated clinically relevant cognitive impairment.
The relationship between decision regret, quality of life, and mindfulness in early-stage breast cancer survivors.
Breast
March 2025
School of Nursing, College of Medicine, National Taiwan University, Taipei, Taiwan; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:
Purpose: The shared decision-making empowers breast cancer patients' autonomy in joining treatment decision. However, unexpected side effects or unsatisfactory outcomes can lead to decision regret. This study examines decision regret levels and its relationship with quality of life, and the impact of mindfulness awareness and self-compassion on this relationship among early-stage breast cancer patients in post-treatment survivorship.
View Article and Find Full Text PDFMobile Electronic Patient-Reported Outcomes and Interactive Support During Breast and Prostate Cancer Treatment: Health Economic Evaluation From Two Randomized Controlled Trials.
JMIR Cancer
March 2025
Division of Nursing, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Background: Digital interventions for supportive care during cancer treatment incorporating electronic patient-reported outcomes (ePROs) can enhance early detection of symptoms and facilitate timely symptom management. However, economic evaluations are needed.
Objective: This study aims to conduct a cost-utility analysis of an app for ePRO and interactive support from the perspective of the payer (Region Stockholm Health Care Organization) and to explore its impact on patient health care utilization and costs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!